Skip to main content

Table 2 Geometric mean titer (GMT) for influenza strains pre-vaccine and post-vaccine

From: Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study

  All patients
(n = 226)
(missinga: 24/28)
bDMARDs monotherapy
(n = 80)
(missinga: 8/14)
bDMARDs + DMARDs
(n = 110)
(missinga: 13/11)
Rituximab
(n = 5)
(missinga: 1/0)
Systemic disorders
(n = 18)
(missinga: 1/1)
Other
(n = 13)
(missinga: 1/2)
Controls
(n = 15)
(missinga: 4/2)
A/Cal H1N1pdm09
 Pre-vaccine 102.4 (92.1–113.9) 110.9 (91.8–134.1) 94.3 (81.2–109.5) 113.1 (59.8–213.9) 125.3 (82.6–190.1) 89.8 (54.9–146.7) 170.4 (100.4–289.2)
 Post-vaccine 147.9 (79.0–165.1) 142.5 (118.7–171.2) 154.0 (132.1–179.6) 105.6 (65.9–169.1) 147.5 (86.6–251.3) 150.2 (81.9–275.3) 287.6 (178.2–464.4)
A/Swi H3N2
 Pre-vaccine 63.0 (58.1–68.4) 63.9 (55.2–73.9) 61.4 (54.9–68.6) 80.0 (32.5–196.9) 57.7 (41.3–80.8) 75.5 (53.3–107.1) 70.5 (46.9–105.9)
 Post-vaccine 87.3 (79.0–96.5) 94.6 (79.5–112.7) 78.9 (69.8–89.1) 139.3 (23.9–812.7) 90.4 (60.4–135.3) 102.9 (52.8–200.6) 183.6 (133.4–252.9)
B/Phu Yamagata
 Pre-vaccine 73.2 (67.8–78.9) 74.8 (65.6–85.3) 71.4 (64.1–79.5) 67.3 (12.9–351.8) 76.8 (57.2–103.1) 75.5 (56.3–101.4) 75.1 (54.2–104.1)
 Post-vaccine 77.4 (71.2–84.1) 75.1 (66.0–84.5) 73.6 (66.2–81.7) 114.5 (31.5–416.5) 86.8 (56.2–134.0) 102.9 (61.1–173.4) 110.2 (76.3–159.1)
  1. Abbreviations: DMARDs disease modifying antirheumatic drugs, bDMARDs biological DMARDs
  2. Data are GMT (95 % CI). a Numbers missing pre-vaccine and post-vaccine, respectively
\